4/21/2021 8:15:02 AM
Summit Therapeutics Commences Previously-announced Rights Offering Of Up To 14.3 Mln Shares
3/17/2021 7:07:41 AM
Summit Therapeutics Q4 Loss Per Share $0.18 Vs Loss $0.34 Last Year
11/23/2020 7:11:37 AM
Summit Therapeutics Appoints Mahkam Zanganeh As COO
6/8/2020 7:31:18 AM
Summit Therapeutics Appoints Michael Donaldson As CFO
12/17/2019 7:18:14 AM
Summit Therapeutics Q3 Loss £7.0 Mln Vs Loss £8.1 Mln Last Year
10/11/2019 7:15:03 AM
Summit Therapeutics Q2 Loss £5.2 Mln; Non-Executive Director Valerie Andrews Steps Down
9/24/2019 7:17:50 AM
Summit Therapeutics To Present Data From Phase 2 Clinical Trial Of Ridinilazole At ID Week 2019
6/12/2019 7:05:43 AM
Summit Therapeutics Posts Loss For Three Months Ended 30 April 2019 Of £4.0 Mln
12/17/2018 2:10:52 AM
Summit Therapeutics CFO Erik Ostrowski To Step Down By End Of Dec. 2018 To Pursue Another Opportunity
9/20/2018 7:05:55 AM
Summit Therapeutics Q2 Profit £26.6 Mln Vs Loss Of £3.3 Mln Last Year
9/5/2018 7:07:22 AM
Summit Therapeutics Nominates SMT-571 As Its Lead Clinical Candidate From First Gonorrhoea Series
8/16/2018 7:11:23 AM
Summit Therapeutics Secures Addl $12 Mln From BARDA For Phase 3 Development Programme Of Ridinilazole
6/27/2018 7:17:20 AM
Summit Therapeutics, Trading Expected To Resume At 7:30 AM ET